Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy

Journal of Urology

Volumn 183, Issue 5, 2010, Pages 1816-1821

  Loeb, Stacy ^a   Kan, Donghui ^b   Yu, Xiaoying ^b   Roehl, Kimberly A ^c   Catalona, William J ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

prostate; prostate specific antigen; prostatectomy; prostatic neoplasms; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; SURVIVAL TIME; TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; HUMANS; INTRAOPERATIVE CARE; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 77950465000     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.01.011     Document Type: Article

References (20)

1. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
2. Khatami A., Aus G., Damber J.E., et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European Randomized Study of Screening for Prostate Cancer, Sweden Section. Int J Cancer 120 (2007) 170
3. Sengupta S., Myers R.P., Slezak J.M., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191
4. Loeb S., Kettermann A., Ferrucci L., et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 54 (2008) 1073
5. Zhang L., Loblaw A., and Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 176 (2006) 1392
6. Klotz L., Zhang L., Lam A., et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28 (2009) 126
7. Smith D.S., and Catalona W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152 (1994) 1732
8. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
9. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156
10. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215
11. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521
12. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440
13. Freedland S.J., Dorey F., and Aronson W.J. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 57 (2001) 476
14. Schmid H.P., McNeal J.E., and Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71 (1993) 2031
15. Goluboff E.T., Heitjan D.F., DeVries G.M., et al. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 158 (1997) 1876
16. Lee W.R., Hanks G.E., Corn B.W., et al. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys 31 (1995) 21
17. Hanks G.E., Hanlon A.L., Lee W.R., et al. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34 (1996) 549
18. Vickers A.J., Savage C., O'Brien M.F., et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27 (2009) 398
19. Link R.E., Shariat S.F., Nguyen C.V., et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 171 (2004) 2234
20. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529